NCI Committed to Increasing Minority Participation in Clinical Trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 7
Volume 4
Issue 7

BETHESDA, Md--Acting NCI Director Edward Sondik announced that the institute is committed to increasing participation of minorities in clinical trials. However, cancer researchers have had only limited success in this effort, he said.

BETHESDA, Md--Acting NCI Director Edward Sondik announced thatthe institute is committed to increasing participation of minoritiesin clinical trials. However, cancer researchers have had onlylimited success in this effort, he said.

Dr. Sondik's remarks were made at a meeting of a new coalition,the Intercultural Cancer Council, sponsored by Baylor Collegeof Medicine, the Susan G. Komen Breast Cancer Foundation, M.D.Anderson Cancer Center, Howard University Hospital, the AmericanCancer Society, and Kellogg Company.

Recent Videos
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
4 experts in this video
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
7 experts are featured in this series.
Related Content